Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:

NCT ID: NCT06317558 Recruiting - NSCLC Clinical Trials

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

NeoIM-Lung
Start date: March 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in NSCLC patients using the real-world data. The main questions it aims to answer are: - What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? - How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.

NCT ID: NCT06317324 Recruiting - Surgery Clinical Trials

Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.

Start date: August 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to compare the prognostic differences between SBRT and Surgery for NSCLC patients with interlobular fissure invasion. The main questions it aims to answer are: 1. Explore the survival differences. 2. Explore of the lung function changes before and after different treatments.

NCT ID: NCT06315686 Recruiting - NSCLC Clinical Trials

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

Start date: September 29, 2022
Phase: Phase 2
Study type: Interventional

Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis, vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to dynamically monitor ctDNA in cerebrospinal fluid (CSF), analyze the ctDNA gene mutation profile of CSF in different patients, and explore the relationship between ctDNA and efficacy and prognosis.

NCT ID: NCT06315010 Not yet recruiting - NSCLC Clinical Trials

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

REPOSE
Start date: August 2024
Phase: Phase 2
Study type: Interventional

REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.

NCT ID: NCT06255951 Recruiting - NSCLC Clinical Trials

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of TY-9591 tablets in healthy subjects

NCT ID: NCT06248606 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

NCT ID: NCT06247280 Recruiting - NSCLC Clinical Trials

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

Start date: June 24, 2022
Phase:
Study type: Observational [Patient Registry]

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.

NCT ID: NCT06246110 Recruiting - NSCLC Clinical Trials

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Start date: February 6, 2024
Phase: Phase 2
Study type: Interventional

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

NCT ID: NCT06239623 Recruiting - Melanoma Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

JSI-1187-101 phase 1 study

NCT ID: NCT06221670 Not yet recruiting - NSCLC Clinical Trials

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.